Genistein as a dietary supplement; formulation, analysis and pharmacokinetics study
The objective of this study is to improve and optimize the formulation of Genistein in capsules in order to result in a better pharmacokinetic profile comparing to existing commercial products. In order to do this, five different formulations of Genistein capsules were developed and examined by revi...
Saved in:
Published in | PloS one Vol. 16; no. 4; p. e0250599 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Public Library of Science
27.04.2021
Public Library of Science (PLoS) |
Subjects | |
Online Access | Get full text |
ISSN | 1932-6203 1932-6203 |
DOI | 10.1371/journal.pone.0250599 |
Cover
Summary: | The objective of this study is to improve and optimize the formulation of Genistein in capsules in order to result in a better pharmacokinetic profile comparing to existing commercial products. In order to do this, five different formulations of Genistein capsules were developed and examined by reviewing their disintegration and dissolution properties. Furthermore, flowability of the powder along with potent incompatibilities between Genistein and its excipients were monitored through their thermal properties. The final formulation of Genistein was quantified using HPLC analysis and then its stability was evaluated thoroughly in real time and accelerated conditions. Finally, with the target to have a product with actual results,
in vitro
and
in vivo
studies were conducted. The final product proved to have better results in disintegration and dissolution. Moreover, R.G.C.C.’s capsules exhibited enhanced action in human cell lines as well as impressive pharmacokinetic results in animal models. The
in vitro
results showed an advantage of the R.G.C.C. product compared to the commercial one, whereas its maximum concertation
in vivo
was determined 34% higher than the commercial one. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Competing Interests: The authors of this manuscript have read the journal’s policy and have the following competing interests: All the authors are employees of Research Genetic Cancer Centre S.A. (R.G.C.C. S.A.) and/or Research Genetic Cancer Centre International (R.G.C.C. International). There are no patents to declare with the developed product by R.G.C.C. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
ISSN: | 1932-6203 1932-6203 |
DOI: | 10.1371/journal.pone.0250599 |